Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Abstract Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were recruited to study viral a...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology Group
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Online Access:	https://doi.org/10.1038/s41467-024-45641-0